42
42
Dec 30, 2019
12/19
by
FBC
tv
eye 42
favorite 0
quote 0
i fill very comfortable to trend dime, regeneron used to be a darling stock in terms of valuation iscome way down, they might have another hit on their hand this drug for eczema. it's headed for a couple billion dollars. it could be a 10 billion-dollar drug. jack: are there any others you just a far away from? >> on this list, they say by which you know, so i don't know anything about the mockup by. of course i'm about i have had big run up so they started to come down a lot but i want to see where that settles. sold her out to me looks a little expensive. abby omitted, i'm not the leading authority on pumps that get inserted to see your heart during surgery to keep blood flowing, we don't want to rely on one product. that has been a little bit of a backlash for a couple of studies that were covered recently at a medical convention. simon wade and see on that one. jack: and united rentals selling it eight times? that's cheap. jack: ideas awakened you right now to improve your portfolio. looking ahead at 2024 innovations and trends that will help shape this 1 in 5 people you meet wear
i fill very comfortable to trend dime, regeneron used to be a darling stock in terms of valuation iscome way down, they might have another hit on their hand this drug for eczema. it's headed for a couple billion dollars. it could be a 10 billion-dollar drug. jack: are there any others you just a far away from? >> on this list, they say by which you know, so i don't know anything about the mockup by. of course i'm about i have had big run up so they started to come down a lot but i want to...
49
49
Dec 28, 2019
12/19
by
FBC
tv
eye 49
favorite 0
quote 0
i fill very comfortable to trend dime, regeneron used to be a darling stock in terms of valuation ismight have another hit on their hand this drug for eczema. it's headed for a couple billion dollars. it could be a 10 billion-dollar drug. jack: are there any others you just a far away from? >> on this list, they say by which you know, so i don't know anything about the mockup by. of course i'm about i have had big run up so they started to come down a lot but i want to see where that settles. sold her out to me looks a little expensive. abby omitted, i'm not the leading authority on pumps that get inserted to see your heart during surgery to keep blood flowing, we don't want to rely on one product. that has been a little bit of a backlash for a couple of studies that were covered recently at a medical convention. simon wade and see on that one. jack: and united rentals selling it eight times? that's cheap. jack: ideas awakened you right now to improve your portfolio. looking ahead at 2024 innovations and trends that will help shape this man: sneezes skip to the good part with alka-se
i fill very comfortable to trend dime, regeneron used to be a darling stock in terms of valuation ismight have another hit on their hand this drug for eczema. it's headed for a couple billion dollars. it could be a 10 billion-dollar drug. jack: are there any others you just a far away from? >> on this list, they say by which you know, so i don't know anything about the mockup by. of course i'm about i have had big run up so they started to come down a lot but i want to see where that...
95
95
Dec 13, 2019
12/19
by
CNBC
tv
eye 95
favorite 0
quote 0
. >> regeneron has been disappointed >> i don't disagree. for me if i look at sort of the political landscape in 2020, i'm not selling biotech and pharma going into weakness in 2020. i think the stock has room to move higher and the current management team will be able to unlock that. >> they do have 30 billion so this could be a transformative being actually sold that and bought ad v. that stock is extremely cheap. >> i don't think you can ignore that the sector, including pharmaceuticals is laboring under the potential price controls the white house is if you look at some of these -- that's are trading at 9 to 12 times earnings it's showing over many years they have lost that halo ofity serving a my now frankly, that may be the opportunity but you have to take a strans on what's going to happen with price controls if you get a progressive president in 2020, this is not going to be the space you want to be in if you get somebody that's more light regulatory, somebody who is pro business, these are going to be home runs at these valuatio val
. >> regeneron has been disappointed >> i don't disagree. for me if i look at sort of the political landscape in 2020, i'm not selling biotech and pharma going into weakness in 2020. i think the stock has room to move higher and the current management team will be able to unlock that. >> they do have 30 billion so this could be a transformative being actually sold that and bought ad v. that stock is extremely cheap. >> i don't think you can ignore that the sector,...
260
260
Dec 31, 2019
12/19
by
CNBC
tv
eye 260
favorite 0
quote 0
of the portfolio, not your retirement portfolio, then it is absolutely worth hunting for the next regeneron without hesitation much more ahead. i have the answer to stocks or bonds. -- is wrong and i'm about to rewrite the script and the game plan to follow when the bear market breaks and it is the most important piece of advice about financial health i could ever give you. many of will you have to take action tomorrow. don't miss this. stick with cramer. for your worst sore throat pain, try vicks vapocool drops. it's not candy, it's powerful relief. ahhh vaporize sore throat pain with vicks vapocool drops and try new vapocool spray. >>> it's time to address a major issue that i have to admit i don't spend enough time discussing here on "mad money. i'm talking about stocks versus bonds. there is a good reason why you don't hear me recommend that you invest in bonds and not just because the show is about stocks since the great recession interest rates have been held down and bond yields like from owning u.s. treasuries have been paltry versus what you could get from safety dividend-paying st
of the portfolio, not your retirement portfolio, then it is absolutely worth hunting for the next regeneron without hesitation much more ahead. i have the answer to stocks or bonds. -- is wrong and i'm about to rewrite the script and the game plan to follow when the bear market breaks and it is the most important piece of advice about financial health i could ever give you. many of will you have to take action tomorrow. don't miss this. stick with cramer. for your worst sore throat pain, try...